MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Axsome Therapeutics Inc

Gesloten

SectorGezondheidszorg

108.96 -1.53

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

108.08

Max

111.99

Belangrijke statistieken

By Trading Economics

Inkomsten

15M

-59M

Verkoop

2.7M

121M

Winstmarge

-48.914

Werknemers

712

EBITDA

14M

-57M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+55.33% upside

Dividenden

By Dow Jones

Volgende Winsten

4 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-179M

5.3B

Vorige openingsprijs

110.49

Vorige sluitingsprijs

108.96

Nieuwssentiment

By Acuity

50%

50%

174 / 376 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Axsome Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 jul 2025, 22:19 UTC

Acquisities, Fusies, Overnames

FCC Approves U.S. Cellular Sale to T-Mobile

11 jul 2025, 17:28 UTC

Belangrijke Marktbewegers

SharpLink Gaming Gains on Ethereum Purchase

11 jul 2025, 16:57 UTC

Winsten

BASF Cuts Outlook on Global Economy Uncertainty

11 jul 2025, 21:45 UTC

Marktinformatie

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 jul 2025, 19:46 UTC

Acquisities, Fusies, Overnames

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 jul 2025, 19:45 UTC

Marktinformatie

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 jul 2025, 19:05 UTC

Marktinformatie

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 jul 2025, 18:18 UTC

Marktinformatie

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 jul 2025, 17:35 UTC

Marktinformatie

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 jul 2025, 17:26 UTC

Marktinformatie

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 jul 2025, 16:53 UTC

Marktinformatie

Crude Futures Add to Early Gains -- Market Talk

11 jul 2025, 16:42 UTC

Winsten

BASF Cuts Outlook on Global Economic Uncertainty

11 jul 2025, 16:08 UTC

Marktinformatie

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 jul 2025, 16:05 UTC

Winsten

BASF Will Publish Half-Year Results on July 30

11 jul 2025, 16:04 UTC

Marktinformatie

Global Equities Roundup: Market Talk

11 jul 2025, 16:04 UTC

Marktinformatie

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 jul 2025, 16:03 UTC

Winsten

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 jul 2025, 16:02 UTC

Winsten

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 jul 2025, 16:01 UTC

Winsten

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 jul 2025, 16:00 UTC

Winsten

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 jul 2025, 15:59 UTC

Winsten

BASF Cuts 2025 Earnings View

11 jul 2025, 15:58 UTC

Winsten

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 jul 2025, 15:57 UTC

Winsten

BASF 2Q EBIT Before Special Items EUR810M

11 jul 2025, 15:54 UTC

Winsten

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 jul 2025, 15:54 UTC

Winsten

BASF 2Q Sales Fell 2.1% on Year

11 jul 2025, 15:53 UTC

Winsten

BASF 2Q Sales EUR15.77B

11 jul 2025, 15:52 UTC

Winsten

BASF: This Was in Line With Consensus Estimates

11 jul 2025, 15:52 UTC

Winsten

BASF 2Q Ebitda Before Special Items EUR1.77B

11 jul 2025, 15:49 UTC

Winsten

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11 jul 2025, 15:41 UTC

Marktinformatie

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Peer Vergelijking

Prijswijziging

Axsome Therapeutics Inc Prognose

Koersdoel

By TipRanks

55.33% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 172 USD  55.33%

Hoogste 210 USD

Laagste 108 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor Axsome Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

16 ratings

15

Buy

1

Hold

0

Sell

Technische score

By Trading Central

107.24 / 112.29Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Strong Bullish Evidence

Sentiment

By Acuity

174 / 376 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.